中医药防治肺动脉高压研究进展
王佳,王淑美,王铭
摘要(Abstract):
肺动脉高压(PAH)是一种严重威胁人类健康的难治性疾病。目前,有关PAH的西医标准化治疗存在诸多弊端;随着中医对PAH的研究深入,中医药有望对PAH的防治发挥多靶点、多途径的调控优势。鉴于此,本文从单味中药和复方制剂的作用机制及临床疗效观察等方面,对中医药防治PAH的现状进行综述,并提出不足与展望。
关键词(KeyWords): 肺动脉高压;中医药;研究现状;综述
基金项目(Foundation): 重庆市自然科学基金面上项目(cstc2019jcyj-msxmX0662);; 重庆市科技局科研机构绩效激励引导专项(cstc2018jxjl130038)
作者(Author): 王佳,王淑美,王铭
参考文献(References):
- [1] GalièN,Humbert M,Vachiery JL,et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol,2016,69(2):424-429.
- [2] Bonow,R.O.BRAUNWALD心脏病学[M].陈灏珠,译.北京:人民卫生出版社,2015.
- [3] Hoeper MM,Humbert M,Souza R,et al. A global view of pulmonary hypertension[J]. Lancet Respir Med,2016(156):306-322.
- [4] Sommer N,Ghofrani HA,Pak O,et al. Current and future treatments of pulmonary arterial hypertension[J]. Br J Pharmacol,2021,178(1):6-30.
- [5]高强,徐巍,王定宇,等.肺动脉高压介入治疗研究进展[J].中国介入心脏病学杂志,2020,28(11):644-646.
- [6]高路,李绍旦,刘毅,等.中药防治肺动脉高压的研究进展[J].中西医结合心脑血管病杂志,2017,15(19):5.
- [7]王蓓蕾.肺动脉高压中医证候分布特点及与疾病预后指标相关性的临床研究初探[D].北京:北京中医药大学,2017.
- [8]牛征,张轩语,付敏,等.中药防治肺动脉高压研究现状及创新药物研发[J].世界科学技术-中医药现代化,2021,23(3):856-865.
- [9]张斌,侯平.中医药治疗肺动脉高压研究进展[J].湖北中医杂志,2016,38(2):78-80.
- [10]刘珺,王博,颜琼枝,等.颜乾麟教授从调补宗气法治疗原发性肺动脉高压经验[J].中国中医急症,2016,25(10):1886-1887.
- [11]张杰,张贺,李秋忆,等.徐浩教授“大气下陷”论治肺动脉高压经验浅析[J].中西医结合心脑血管病杂志,2019,17(8):1271-1273.
- [12]谈佳玮,车志英,李顺景.王国斌教授运用桃红四物汤加减治疗肺动脉高压经验[J].中医学报,2016,31(11):1691-1694.
- [13]魏本君,杨玲玲,田琴,等.辛开苦降补气法在肺动脉高压中的运用[J].世界最新医学信息文摘,2021,21(5):223-224.
- [14]杨小晖,黄鹏,罗金文.三七总皂甙对肺动脉高压大鼠肺动脉病理的影响[J].中国医师杂志,2015,21(10):1532-1535.
- [15] Zhao S,Zheng MX,Chen HE,et al. Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension[J].Chin J Integr Med,2015,21(2):147-151.
- [16] Xu YX,Lin L,Tang LL,et al. Notoginsenoside R1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of ERK[J]. The American Journal of Chinese Medicine,2014,42(4):799-816.
- [17] Zheng M,Zhao M,Tang L,et al. Ginsenoside Rg1 attenuates hypoxia and hypercapnia-induced vasoconstriction in isolated rat pulmonary arterial rings by reducing the expression of p38[J]. J Thorac Dis,2016,8(7):1513-1523.
- [18] Feng EZ,Yang SY,Huang NX,et al. Plasma endothelin-1and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation[J].Chinese journal of applied physiology,2014,30(6):532-537.
- [19]黄志宏,汤泰秦,黄纳斯,等.川芎嗪对缺氧肺动脉高压大鼠血浆内皮素、降钙素基因相关肽水平的影响[J].广州中医药大学学报,1998,15(4):275-276.
- [20]刘礼姣,谢利剑.丹参酮ⅡA治疗肺动脉高压作用机制[J].儿科药学杂志,2021,27(6):60-63.
- [21] Yuan T,Chen Y,Zhang H,et al. Salvianolic acid A,a component of salvia miltiorrhiza,Attenuates endothelial-mesenchymal transition of HPAECs induced by hypoxia[J]. Am J Chin Med,2017,45(6):1185-1200.
- [22] Xu DG,Li Y,Zhang B,et al. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats[J]. International Journal of Medical Sciences,2016,13(12):942-954.
- [23]李泽荣,乔文梅,王诚淏,等.白藜芦醇抗肺动脉高压作用机制研究进展[J].中国药师,2020,23(3):523-525.
- [24] Guan ZJ,Shen L,Liang H,et al. Resveratrol inhibits hypoxiainduced proliferation and migration of pulmonary artery vascular smooth muscle cells by inhibiting the phosphoinositide3-kinase/protein kinase B signaling pathway[J]. Molecular medicine reports,2017,16(2):1153-1160.
- [25]井丽巍,李瑞雪,胡艳丽,等.牛磺酸治疗肺动脉高压的研究进展[J].黑龙江医药,2015,28(4):735-737.
- [26] Gao JL,Chen G,He HQ,et al. Therapeutic effects of breviscapine in cardiovascular diseases:A review[J]. Frontiers in Pharmacology,2017(8):69-40.
- [27]苏巧俐,程德云,郑碧霞,等.灯盏细辛对大鼠低氧性肺动脉高压的治疗效应[J].华西医学,2007,22(1):113-114.
- [28] Wang XW,Yang YC,Yang DP,et al. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphatedependent protein kinase type 1[J]. Journal of Vascular Surgery,2016,64(5):1468-1477.
- [29]张晓丹,杜伟,张晨,等.葛根素对缺氧性肺动脉高压及伴随的肺纤维化的作用[J].中国中药杂志,2018,43(12):2618-2623.
- [30]王贺,贾微,侯平.茯苓甘草汤治疗肺动脉高压之探析[J].湖北中医杂志,2016,38(4):54-56.
- [31]周向锋,王良兴,林全.桂枝茯苓丸对低O2高CO2大鼠肺动脉血管重构的影响及机理[J].中国中医基础医学杂志,2006,12(4):268-269.
- [32]张文曦.复方薤白胶囊治疗肺动脉高压抗内皮细胞凋亡的研究[D].南京:南京中医药大学,2009.
- [33]吴周烨.基于MicroRNA-130a靶向调节Gax探讨复方薤白胶囊对肺动脉高压血管重构的作用[D].南京:南京中医药大学,2020.
- [34]李松林,韩雪,李文娣,等.葛根芩连汤治疗肺动脉高压的作用机制研究[J].哈尔滨商业大学学报:自然科学版,2021,37(2):131-138.
- [35]孙晓萍,常秀娟,周军,等.芪白平肺颗粒对肺动脉高压大鼠的影响及机制研究[J].中药药理与临床,2016,32(2):189-192.
- [36]冷萍,王一帆,黄佰超,等.七龙天对实验性肺动脉高压大鼠ET-1、NOS的影响[J].辽宁中医杂志,2016,43(7):1486-1489.
- [37]方居正.芪苈强心胶囊对肺动脉高压症患者的疗效分析[J].络病学基础与临床研究,2011:321-322.
- [38]常生杰.三拗芎葶合剂对低氧性肺动脉高压大鼠血浆心房利钠肽、C型利钠肽影响的实验研究:三拗芎葶合剂治疗痰瘀阻肺型肺胀临床观察[D].成都:成都中医药大学,2007.